|
|
Substance Name: Heparin
RN: 9005-49-6
InChIKey: HTTJABKRGRZYRN-UHFFFAOYSA-N
Note
- A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.
Molecular Formula
- Unspecified
Molecular Weight
- 1134.9248
Classification Codes
- Anticoagulant
- Anticoagulants
- Antithrombotic
- Antiviral (COVID-19)
- Cardiovascular Agents
- Drug / Therapeutic Agent
- Fibrin Modulating Agents
- Fibrinolytic Agents
- Hematologic Agents
- Human Data
- Mutation Data
- Natural Product
- Reproductive Effect
* denotes mobile formatted website
Links to Resources
NLM Resources (File Locators)
Regulatory Agencies (Superlist Locators)
Other Resources (Internet Locators)
Search for this InChIKey on the Web
Names and Synonyms
Results Name
- Heparin
Name of Substance
- Adomiparin [USAN]
- Bemiparin
- Certoparin
- CY 222
- Fluxum
- Heparin
- Heparin [BAN]
- Parnaparin
- Reviparin
- Sandoparin
- Semuloparin [USAN:INN]
- Tinzaparin
MeSH Heading
- Heparin
Synonyms
- Adomiparin
- alpha-Heparin
- Ardeparin
- Arteven
- AVE-5026
- Bemiparin
- Certoparin
- Clexane
- Clivarin
- Clivarine
- CY 216
- CY 222
- Dalteparin
- Depo-Heparin
- EINECS 232-681-7
- Eparina
- Eparina [DCIT]
- Fluxum
- FR 860
- Fragmin A
- Fragmin B
- Fraxiparin
- Hed-heparin
- Heparin CY 216
- Heparin sulfate
- Heparina
- Heparina [INN-Spanish]
- Heparinate
- Heparine
- Heparine [INN-French]
- Heparinic acid
- Heparinum
- Heparinum [INN-Latin]
- Hepathrom
- HSDB 3094
- KB 101
- Lipo-hepin
- Liquaemin
- Liquemin
- LMWH
- M 118
- M 118REH
- M118
- Multiparin
- Nadroparin
- Nadroparine
- Novoheparin
- Octaparin
- OP 386
- OP 622
- Pabyrin
- Parnaparin
- Parvoparin
- Pularin
- Reviparin
- Sandoparin
- Semuloparin
- Subeparin
- Sublingula
- Thromboliquine
- Tinzaparin
- Triofiban
- UNII-1K5KDI46KZ
- UNII-4QW4AN84NQ
- UNII-5R0L1D739E
- UNII-7UQ7X4Y489
- UNII-9816XA9004
- UNII-E47C0NF7LV
- UNII-M316WT19D8
- UNII-P776JQ4R2F
- UNII-S79O08V79F
- UNII-T2410KM04A
- UNII-V72OT3K19I
- UNII-VL0L558GCB
- Vetren
- Vitrum AB
Systematic Name
- Heparin
Registry Numbers
CAS Registry Number
- 9005-49-6
FDA UNIIs
- 1K5KDI46KZ
- 4QW4AN84NQ
- 5R0L1D739E
- 7UQ7X4Y489
- 9816XA9004
- E47C0NF7LV
- M316WT19D8
- P776JQ4R2F
- S79O08V79F
- T2410KM04A
- V72OT3K19I
- VL0L558GCB
Other Registry Numbers
- 104521-37-1
- 11078-24-3
- 1108625-99-5
- 1108626-06-7
- 11129-39-8
- 37324-73-5
- 9075-96-1
- 91449-79-5
System Generated Number
- 0009005496
Structure Descriptors
InChI
InChI=1S/C26H42N2O37S5/c1-4(30)27-7-9(31)13(6(56-23(7)39)3-55-67(43,44)45)58-26-19(65-70(52,53)54)12(34)16(20(62-26)22(37)38)60-24-8(28-66(40,41)42)15(63-68(46,47)48)14(5(2-29)57-24)59-25-18(64-69(49,50)51)11(33)10(32)17(61-25)21(35)36/h5-20,23-26,28-29,31-34,39H,2-3H2,1H3,(H,27,30)(H,35,36)(H,37,38)(H,40,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)InChIKey
HTTJABKRGRZYRN-UHFFFAOYSA-NSmiles
CC(=O)Toxicity
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
man | TDLo | intravenous | 3536units/kg/ (3536units/kg) | Southern Medical Journal. Vol. 80, Pg. 1450, 1987. | |
man | TDLo | subcutaneous | 1857units/kg/ (1857units/kg) | Southern Medical Journal. Vol. 80, Pg. 1450, 1987. | |
man | TDLo | subcutaneous | 1857units/kg/ (1857units/kg) | CARDIAC: OTHER CHANGES | Southern Medical Journal. Vol. 80, Pg. 1450, 1987. |
mouse | LD50 | intraperitoneal | 1900mg/kg (1900mg/kg) | BEHAVIORAL: MUSCLE WEAKNESS BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) | Nippon Yakurigaku Zasshi. Japanese Journal of Pharmacology. Vol. 60, Pg. 507, 1964. |
mouse | LD50 | intravenous | 500mg/kg (500mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | Arzneimittel-Forschung. Drug Research. Vol. 36, Pg. 1366, 1986. |
mouse | LD50 | subcutaneous | 500mg/kg (500mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: MUSCLE WEAKNESS | Arzneimittel-Forschung. Drug Research. Vol. 36, Pg. 1366, 1986. |
rat | LD50 | oral | 1950mg/kg (1950mg/kg) | German Offenlegungsschrift Patent Document. Vol. #2636091, | |
rat | LDLo | intraperitoneal | 420mg/kg (420mg/kg) | Toxicology and Applied Pharmacology. Vol. 1, Pg. 156, 1959. | |
women | TDLo | subcutaneous | 30uL/kg/5D-I (0.03mL/kg) | SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" | British Journal of Haematology. Vol. 82, Pg. 620, 1992. |
women | TDLo | subcutaneous | 48mg/kg/20D-I (48mg/kg) | SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" BLOOD: HEMORRHAGE | Australian and New Zealand Journal of Medicine. Vol. 28, Pg. 59, 1998. |
women | TDLo | subcutaneous | 1000units/kg/ (1000units/kg) | Southern Medical Journal. Vol. 80, Pg. 1450, 1987. |